Emily Han-Chung Hsiue

Author

Johns Hopkins University ORCID

Also Known As

E. Hsiue, E.H.C. Hsiue, Emily Han-Chung Hsiue, Emily Hsiue, H-C. Hsiue, H.-C. Hsiue, Han-Chung Hsiue, Han‐Chung Hsiue

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Howard Hughes Medical Institute Bloomberg (United States)

About

Emily Han-Chung Hsiue is an author at Johns Hopkins University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	191
2	Immunology	2	2	72
3	Engineering	1	1	15
4	Biostatistics	1	1	15
5	Cell Biology	1	1	19

Emily Han-Chung Hsiue

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Justina X. Caushi, Jiajia Zhang, Zhicheng Ji, Nature	2021	505
Targeting a neoantigen derived from a common <i>TP53</i> mutation Emily Han-Chung Hsiue, Katharine M. Wright, Jacqueline Douglass, Science	2021	332
Bispecific antibodies targeting mutant<i>RAS</i>neoantigens Jacqueline Douglass, Emily Han-Chung Hsiue, Brian J. Mog, Science Immunology	2021	162
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses Arbor G. Dykema, Boyang Zhang, Bezawit A. Woldemeskel, Journal of Clinical Investigation	2021	92
Targeting loss of heterozygosity for cancer-specific immunotherapy Michael S. Hwang, Brian J. Mog, Jacqueline Douglass, Proceedings of the National Academy of Sciences	2021	70
Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes Sheng‐Yuan Ruan, Yao‐Wen Kuo, Chun‐Ta Huang, International Journal of Antimicrobial Agents Antifungal AgentFungal PathogenAntifungal AgentsVaginitisClinical Mycology	2009	58
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers Suman Paul, Alexander H. Pearlman, Jacqueline Douglass, Science Translational Medicine ImmunologyImmunotherapeuticsCd4 T Cell ResponsesImmune Cell TherapyT Cells	2021	53
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Nature Communications	2021	38
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients Tinghui Wu, Emily Han-Chung Hsiue, Jih‐Hsiang Lee, Clinical Lung Cancer Best ResponseMedicineCancer RecurrenceCancer ManagementPathology	2018	30
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen Katharine M. Wright, Sarah R. DiNapoli, Michelle S. Miller, Nature Communications	2023	25

Page 1